A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer

A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer

Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide.

Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.

Inclusion Criteria:

• histologically or cytologically confirmed extensive disease of Small cell lung cancer
• no prior chemotherapy or radiotherapy for lung
• measurable lesion for RECIST
• over 18 years
• ECOG 0~2
• expected life span more than 3 months

Exclusion Criteria:

• acute or active infection
• uncontrolled cerebral nerve symptoms or metastasis
• significant myocardial infarction or cardiac disease within 12 months